Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – ,
Europe: Europe
European cloud company seeks investment and acquisition.
The company is an expert in the European data center and cloud market. Since its establishment, the company has been committed to promoting innovative technologies focusing on sustainable development and information security. The company develops and operates energy-efficient, secure, scalable IT infrastructure and data center solutions for utility companies. The company has opened up a new business model and revenue source for the global public utilities. The key technology of the company lies in the hot water cooling technology, which uses the imported hot water to cool the IT equipment in the data center. The company can efficiently collect the server waste heat and convert it into an environmentally friendly heating source to realize waste heat recovery and reuse. The company mainly has two major data center products: micro data center: it can be formed on a single machine and used in office space, or it can be planned to be used in large-scale and highly flexible data center construction projects. Container data center: a multi-purpose solution specially designed for data center projects with rapid deployment and high mobility requirements.
Europe: Europe
European machinery manufacturing seeks investment or acquisition.
The company is a European clamping device solution supplier, providing customers with firm, universal and stable clamping device and system solutions in high-precision dimensional control and management. The company has become a global supplier with a number of patented inventions. Its technical R&D team can provide complete solutions from development, design, procurement, assembly, measurement and control to after-sales service at any time. The target company has four unique solutions and patented technologies. The products of the company are mainly used in the automotive industry, aerospace, plastic industry and general manufacturing fields. The main customers and partners are world-famous automobile OEMs and spare parts manufacturers.
Europe: Germany
German biomedicine company seeks investment.
The company is a chip laboratory for virus microbial detection, focusing on the timely diagnosis equipment of single molecule sensitivity. Its advantages are
1 single molecule sensitivity: direct single molecule counting without nucleic acid extraction or PCR amplification
2 data analysis network security: safe and convenient desensitization data sharing, convenient for users to build a real-time infectious disease monitoring network
3. Covering large range in single test: up to 120 kinds of viral microorganisms can be detected in a single test, covering almost all viruses, bacteria and parasites endangering human health
4. 15 minutes from the sample to the result: it can respond quickly to the epidemic and formulate treatment and isolation plans
5. Low cost (8 yuan / time / microorganism)
The company has a patented technology, which is the industry's only multi fluorescent labeling coding technology, can detect all dangerous viruses and microorganisms in the human body and make immediate diagnosis at the bedside. It is 40 times cheaper and 20 times faster than the existing scheme. It is predicted that it will occupy 6.3-10.5 billion in infectious disease diagnosis. The company is currently the only molecular diagnostic company that can balance high flux, fast, low cost and accuracy. The company is also a an all-platform company, earning revenue from equipment, consumables, customized development fees and third-party licensing fees. The company is a global innovation company, R&D in Germany and made in China.
1 single molecule sensitivity: direct single molecule counting without nucleic acid extraction or PCR amplification
2 data analysis network security: safe and convenient desensitization data sharing, convenient for users to build a real-time infectious disease monitoring network
3. Covering large range in single test: up to 120 kinds of viral microorganisms can be detected in a single test, covering almost all viruses, bacteria and parasites endangering human health
4. 15 minutes from the sample to the result: it can respond quickly to the epidemic and formulate treatment and isolation plans
5. Low cost (8 yuan / time / microorganism)
The company has a patented technology, which is the industry's only multi fluorescent labeling coding technology, can detect all dangerous viruses and microorganisms in the human body and make immediate diagnosis at the bedside. It is 40 times cheaper and 20 times faster than the existing scheme. It is predicted that it will occupy 6.3-10.5 billion in infectious disease diagnosis. The company is currently the only molecular diagnostic company that can balance high flux, fast, low cost and accuracy. The company is also a an all-platform company, earning revenue from equipment, consumables, customized development fees and third-party licensing fees. The company is a global innovation company, R&D in Germany and made in China.
Europe: Denmark
Danish semiconductor R&D company seeks partners in China
The company has a third-generation semiconductor Chinese R&D team, focusing on nano-sized surface treatment, and its core technology is the preparation of micro and nanostructures on GaN and SiC surfaces. Compared with the device without surface structure treatment of n-GaN, the light output power of vertical blue LED is at least doubled; The el of encapsulated LED devices is enhanced by > 17%; Suitable for different chip designs such as side flow, vertical, or thin-film flip-chip; The method is fast (< 1 hour), and its cost is low and can be used in a large area; Existing production lines can be used. The current founder seeks domestic partners.
Europe: Croatia
Croatian processing and manufacturing company with a long-history seeks financial support and land expansion.
Founded in 1916, the company has long been synonymous with high-quality tableware, kitchenware, woodworking machinery, tools and industrial knifes. The company has complete tableware production facilities, with an annual output of more than 10 million pieces, about 300 workers and an abundant plant area. It provides a full range of training services for workers, including component installation, equipment installation, start-up, industrial consulting and other services. It has long-term cooperation with famous companies such as Stihl, Villeroy & Boch, Rosenthal and Sheffield Metals in the UK, and exports different products to more than 20 countries around the world. The company hopes to expand its market, obtain franchise rights, or build its own sales center. The company is located in Central Europe and the Balkans, closely connected with ports, airports and highways, has a market of more than 500 million consumers, can fully vertically integrate all metal processing technologies, has EU financial support, has maintained a good relationship with scientific research institutes, and exports 70% of its products. The company has 37,000 square meters of land, 20,000 square meters of factories, more than 470 machines, sufficient space for technology development, and energy infrastructure: (4 MW electricity, pneumatic system (6 bar), tap water and cooling water). We are now seeking financial support for company expansion and plant expansion.
Europe: Croatia
Croatian toy manufacturing company with a long history seeks partners or acquisition.
The private company is created based on robot technology for toys, and STEM fields related teaching materials. The company has more than 25 years of experience in this field. Some hardware and software solutions developed by the company can be integrated with "fischertechnik" products.
Europe: Britain
British medical equipment company seeks for investment.
The company is developing a pump that can be implanted directly into the failing heart to treat advanced chronic heart failure. The company aims to apply novel technologies and designs to produce ventricular assist devices (VADs) with obvious advantages over existing methods, including less invasive surgery, reduced thrombosis and control systems optimized for quality of life. The company is raising £ 7.5 million and is now steadily realizing the first implantation of the company's products in the human body in 2021.
Europe: Britain
British clinical biotechnology company seeks for acquisition.
The company is a UK based clinical biotechnology company dedicated to the development of new anti-infectives. Founded in the UK in 1997, it was listed on the London Stock Exchange (LSE) sub market alternative investment market (AIM) in 2017, with a market value of £ 19 million. In 2018, the first new drug for research (IND) was successfully launched in the United States, has obtained fast track qualification, and is starting the planned clinical plan. The pilot drug code named XF-XX has completed a clinical trial funded by the U.S. government. Different from traditional antibiotics, XF-XX shows excellent resistance to a specified bacterial in the laboratory - producing a series of potential low bacterial resistance, which can be used to prevent and treat methicillin resistant Staphylococcus aureus (MRSA) infection. Compared with traditional antibiotics, XF platform has the advantages of killing bacteria quickly, killing bacteria in any growth period and killing bacteria in staphylococcal bacterial biofilm. It is active against all Gram-positive bacteria tested so far and selected Gram-negative bacteria. No bacterial (MRSA) resistance was found. The company continued to strengthen its patent rights and granted XF biofilm patents in Canada in 2018, bringing the total number of patents granted by XF platform to 95.
Europe: Finland
Finish medical R&D company seeks domestic investment or acquisition.
A private company, which is headquartered in Turku, Finland, dedicated to providing innovative diagnostic tools for routine clinical diagnosis and research. Based on its proprietary technology, the company has developed and commercialized the next generation of multifunctional micro detection tools. The advantages of this technology enable it to overcome the performance limitations of the previous generation test in terms of sensitivity, accuracy, ease of use and cost efficiency.
The testing equipment developed by the company has passed ISO 13485:2016 and ISO 9001:2015. This equipment is a cathode electrochemiluminescence instrument that can be used to measure the concentration of components in blood. The technology can be used for animal epidemic prevention. It is convenient and fast to use. The results can be obtained in 5-10 minutes with reliable accuracy. It can be viewed at any time on the independent display screen or mobile phone application on the equipment.
If the matching detection box is used together (the antibody has been wrapped on the chip without calibration), the analyzer can also be used to detect human C-reactive protein (CRP). Results can be displayed in 6-12 minutes from a full blood sample. It can be used to triage patients to reduce uncertainty and avoid unnecessary antibiotic use.
The testing equipment developed by the company has passed ISO 13485:2016 and ISO 9001:2015. This equipment is a cathode electrochemiluminescence instrument that can be used to measure the concentration of components in blood. The technology can be used for animal epidemic prevention. It is convenient and fast to use. The results can be obtained in 5-10 minutes with reliable accuracy. It can be viewed at any time on the independent display screen or mobile phone application on the equipment.
If the matching detection box is used together (the antibody has been wrapped on the chip without calibration), the analyzer can also be used to detect human C-reactive protein (CRP). Results can be displayed in 6-12 minutes from a full blood sample. It can be used to triage patients to reduce uncertainty and avoid unnecessary antibiotic use.
Europe: Britain
British biomedicine company seeks Chinese Partner.
The firm is a Contract Manufacture Organization (CMO) headquartered in the UK, manufacturing and sterile filling bottles for clinical trials and small volume commercial supply. The company was founded in 2011, has sales offices in Boston, the United States. The turnover in 2019 exceeded USD 10 million, and the EBITDA in 2019 exceeded about USD 1.4 million. Core business: sterile production, analysis and microbiological testing, clinical trial services, (CTS): labeling and packaging, release of qualified personnel (QP). The company specializes in production of liquid, lyophilized powder, cytotoxicity, chemical and biopharmaceutical products, including lyophilized powder or liquid, biological agents (peptides, proteins, antibodies, nucleic acids), small molecules and efficient cytotoxins. It has professional facilities: two dust-free rooms with freeze dryer and special cytotoxic and non cytotoxic clean rooms. Test capability: release test, including HPLC, SDS PAGE, ELISA, microbial detection - sterility and endotoxin, etc.
Europe: Italy
Italian sheet metal equipment manufacturer selling majority of the share.
The company was founded in 2001, produces sheet metal equipment, and has unique patented technology. In the more than ten years since entering the Chinese market, the company has completed many landmark construction projects and key projects, such as the CITIC Tower project.
At present, there are 7 domestic production lines that can produce products with specifications of "1200 * 2400 (mm)" and above.Aquisition can help to rapidly localize the products, to effectively reduce the price.
The main production facilities are located in the center of the Modena's ceramic zone in northern Italy. In fy2017, the company's revenue was € 83.2 million and EBITDA was € 13.2 million. The founding family is seeking to sell a majority stake (up to 70%). Over the last years income increased from 48.8 million Euros to 83.2 million Euros. EBITDA also increased from € 10.8 million in fy2015 to € 13.3 million in fy2017. Net debt increased from € 9.8 million to € 23.1 million in fy2017, mainly due to new shareholder loans of € 13 million. In 2017, 69% of the revenue was generated in overseas markets. European countries accounted for 31% of the revenue in fiscal 2017, with Spain, Poland, Germany, and France as the main markets. The Far East accounts for 13% of revenue, and the main markets are China, India, South Korea, and Japan. In fiscal 2017, North American sales increased by 36% to € 8.1 million.
At present, there are 7 domestic production lines that can produce products with specifications of "1200 * 2400 (mm)" and above.Aquisition can help to rapidly localize the products, to effectively reduce the price.
The main production facilities are located in the center of the Modena's ceramic zone in northern Italy. In fy2017, the company's revenue was € 83.2 million and EBITDA was € 13.2 million. The founding family is seeking to sell a majority stake (up to 70%). Over the last years income increased from 48.8 million Euros to 83.2 million Euros. EBITDA also increased from € 10.8 million in fy2015 to € 13.3 million in fy2017. Net debt increased from € 9.8 million to € 23.1 million in fy2017, mainly due to new shareholder loans of € 13 million. In 2017, 69% of the revenue was generated in overseas markets. European countries accounted for 31% of the revenue in fiscal 2017, with Spain, Poland, Germany, and France as the main markets. The Far East accounts for 13% of revenue, and the main markets are China, India, South Korea, and Japan. In fiscal 2017, North American sales increased by 36% to € 8.1 million.
Europe: Netherlands
Dutch radiofrequency technology company is seeking investment.
The team is an independent R&D group of a well-known semiconductor company in the Netherlands, in wireless communication, radio frequency technology and mixed signal processing. This project is suitable for listed or planned listed technology enterprises. The fast-forming European R&D center can effectively promote technology iteration and new product launch, and has independent core technology IP. The R&D team has Chinese technology leaders who have lived in Europe for many years as its core, and attracts high-level European R&D engineers. It can quickly form a R&D team of 6-10 people in 3-6 months, and the forming team can generally complete the design, development and testing of new products in 6-12 months. A mature 6-person R&D team probably has a budget of 4 million RMB/ year. The R&D center is recommended to settle in Eindhoven High-tech Park in the Netherlands.
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us